- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Design Therapeutics Inc (DSGN)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: DSGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.73% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 537.17M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 3 | Beta 1.64 | 52 Weeks Range 2.60 - 10.31 | Updated Date 12/14/2025 |
52 Weeks Range 2.60 - 10.31 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.49% | Return on Equity (TTM) -29.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 332941228 | Price to Sales(TTM) 22642.01 |
Enterprise Value 332941228 | Price to Sales(TTM) 22642.01 | ||
Enterprise Value to Revenue 11004.35 | Enterprise Value to EBITDA -0.84 | Shares Outstanding 56963757 | Shares Floating 26602075 |
Shares Outstanding 56963757 | Shares Floating 26602075 | ||
Percent Insiders 35.97 | Percent Institutions 58.98 |
About Design Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-03-26 | Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Mr. Pratik Shah Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.designtx.com |
Full time employees 55 | Website https://www.designtx.com | ||
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

